Eli Lilly and Biogen Announce Major Biotech Acquisitions, Boosting Market Confidence

The announced acquisitions of Centessa Pharma by Eli Lilly and Apellis Pharma by Biogen have driven a 7% rally in the biotech XBI Index, ending the quarter with significant gains. This consolidation trend indicates strategic expansion amid a cautious FDA approval environment. Investors should monitor how these mergers influence biotech innovation and approval rates moving forward.